Scientific Sessions

Examine genomic and epigenomic alterations contributing to cancer development and progression. Topics include next-generation sequencing, somatic mutations, chromosomal abnormalities, DNA methylation, histone modifications, gene regulation, transcriptomics, and comprehensive molecular profiling. The session highlights technologies enabling tumor characterization, biomarker discovery, patient stratification, and precision treatment strategies.

Explore individualized approaches to cancer prevention, diagnosis, and treatment based on tumor biology and patient-specific characteristics. Discussions include genomic profiling, actionable mutations, biomarkers, targeted therapies, treatment selection, molecular tumor boards, and personalized clinical decision-making. The session highlights emerging strategies designed to improve therapeutic precision and patient outcomes.

Investigate the complex cellular and molecular interactions between tumors and their surrounding microenvironment. Topics include cancer-associated fibroblasts, extracellular matrix, immune cells, endothelial cells, angiogenesis, metabolic signaling, and stromal remodeling. Discussions will examine how the tumor microenvironment influences cancer progression, immune evasion, metastasis, therapeutic response, and resistance.

Explore interactions between malignant cells and the immune system, including immune surveillance, tumor antigen recognition, immune suppression, and immune escape. This session covers fundamental cancer immunology and emerging immuno-oncology approaches, highlighting mechanisms that activate anti-tumor immunity and support development of innovative immune-based cancer treatments.

Discuss advances in immune checkpoint blockade targeting pathways including PD-1, PD-L1, and CTLA-4. Topics include mechanisms of response and resistance, predictive biomarkers, combination immunotherapy, treatment sequencing, immune-related adverse events, and emerging strategies designed to expand checkpoint inhibitor effectiveness across tumor types and patient populations.

Explore advances in genetically engineered cellular therapies, particularly CAR-T cell treatment for hematologic and solid malignancies. Discussions include CAR design, target selection, manufacturing, patient selection, persistence, cytokine release syndrome, neurotoxicity, treatment resistance, and next-generation cellular therapies designed to enhance efficacy, safety, scalability, and accessibility.

Examine emerging therapeutic cancer vaccines and innovative immunotherapy platforms designed to stimulate tumor-specific immune responses. Topics include personalized neoantigen vaccines, mRNA technologies, dendritic-cell approaches, viral platforms, immune modulation, combination strategies, and clinical development. The session highlights opportunities for creating durable and individualized anti-cancer immune responses.

Focus on therapeutic strategies targeting molecular alterations responsible for cancer growth and survival. Discussions include kinase inhibitors, signaling pathway inhibitors, actionable mutations, molecular targets, patient selection, treatment combinations, acquired resistance, and emerging targeted agents. The session highlights how molecular characterization can guide treatment selection and therapeutic development.

Explore antibody–drug conjugates and emerging biologic therapies designed to selectively deliver therapeutic payloads to cancer cells. Topics include antibody engineering, target selection, linker technologies, cytotoxic payloads, bispecific antibodies, pharmacology, resistance, toxicity, and clinical development of next-generation biologics supporting precision cancer treatment.

Examine the journey from identification of promising cancer targets through discovery, optimization, preclinical testing, and clinical development. Topics include target validation, screening technologies, medicinal chemistry, drug design, experimental models, translational research, and innovative therapeutic platforms. Discussions highlight strategies for accelerating development of effective oncology treatments.

Investigate biological mechanisms responsible for primary and acquired resistance to cancer treatments. Topics include tumor heterogeneity, clonal evolution, genetic alterations, adaptive signaling, drug efflux, immune escape, and microenvironmental influences. The session explores combination therapies, treatment sequencing, biomarkers, and emerging strategies designed to overcome therapeutic resistance.

Explore liquid biopsy technologies for minimally invasive cancer detection, monitoring, and molecular characterization. Discussions include circulating tumor DNA, circulating tumor cells, cell-free DNA, minimal residual disease, treatment response, recurrence monitoring, and biomarker discovery. The session highlights emerging applications of liquid biopsy in precision oncology and longitudinal patient management.

Focus on the discovery, validation, and clinical implementation of biomarkers supporting cancer diagnosis, prognosis, treatment selection, and monitoring. Topics include predictive biomarkers, molecular testing, companion diagnostics, patient stratification, assay validation, and emerging technologies. Discussions highlight how biomarker-driven approaches can support individualized therapeutic decisions and clinical development.

Explore innovative approaches for identifying cancer at earlier and potentially more treatable stages. Topics include population screening, molecular diagnostics, circulating biomarkers, multi-cancer detection, advanced imaging, risk assessment, artificial intelligence, and emerging technologies. The session examines opportunities and challenges in improving early diagnosis, screening effectiveness, accessibility, and clinical outcomes.

Examine applications of artificial intelligence and machine learning throughout cancer research and clinical care. Topics include predictive modeling, biomarker discovery, drug development, patient stratification, treatment response prediction, data integration, medical imaging, and computational analysis. Discussions highlight emerging AI methodologies supporting precision oncology and translational cancer research.

Explore the integration of digital pathology, computational methods, and artificial intelligence into cancer diagnosis and research. Topics include whole-slide imaging, computational histopathology, automated tumor classification, image analysis, spatial profiling, quantitative pathology, and machine learning. The session highlights technologies improving diagnostic consistency, research capabilities, and data-driven oncology.

Discuss advances in imaging technologies supporting cancer detection, characterization, staging, treatment planning, and monitoring. Topics include MRI, CT, PET, molecular imaging, radiomics, artificial intelligence, image-guided procedures, and emerging imaging biomarkers. The session examines approaches enabling more accurate tumor assessment, earlier diagnosis, treatment response evaluation, and personalized clinical management.

Explore advances in radiation-based cancer treatment, including precision radiotherapy, image-guided radiation therapy, stereotactic techniques, proton therapy, adaptive radiotherapy, and treatment planning. Discussions address dose optimization, tumor targeting, normal tissue protection, combination therapies, biomarkers, and emerging technologies designed to improve tumor control while reducing treatment-related complications.

Examine contemporary advances in surgical management of cancer, including laparoscopic, robotic, minimally invasive, image-guided, and organ-preserving approaches. Topics include surgical innovation, precision techniques, perioperative care, multidisciplinary treatment, patient selection, and emerging technologies. The session highlights strategies designed to improve tumor control, recovery, safety, and long-term patient outcomes.

Explore evolving approaches to chemotherapy and multimodal cancer treatment. Discussions include treatment selection, dosing strategies, combination regimens, treatment sequencing, toxicity management, pharmacological optimization, and integration with targeted therapy, immunotherapy, and radiation. The session highlights evidence-based approaches for maximizing therapeutic benefit while reducing treatment-related toxicity and resistance.

Explore advances in breast cancer biology, molecular classification, diagnosis, and personalized treatment. Topics include genetic risk, biomarkers, imaging, molecular subtypes, targeted therapies, endocrine therapy, immunotherapy, surgery, radiation, and emerging treatment approaches. Discussions highlight multidisciplinary strategies for improving diagnosis, therapeutic selection, disease control, and patient outcomes.

Focus on contemporary advances in lung cancer and thoracic malignancies, including biology, diagnosis, screening, molecular profiling, and treatment. Topics include targeted therapies, immunotherapy, surgery, radiation oncology, biomarkers, liquid biopsy, resistance mechanisms, and multidisciplinary management strategies for improving outcomes in non-small cell and small cell lung cancers.

Explore advances in gastrointestinal and colorectal cancer research spanning molecular biology, early detection, biomarkers, prevention, diagnosis, and treatment. Topics include genomic alterations, liquid biopsy, targeted therapies, immunotherapy, surgery, radiation, microbiome interactions, and emerging multidisciplinary strategies designed to improve therapeutic outcomes and personalized patient management.

Discuss advances in ovarian, endometrial, cervical, and other gynecologic malignancies. Topics include molecular classification, hereditary cancer risk, biomarkers, early detection, surgery, chemotherapy, targeted therapies, immunotherapy, PARP inhibitors, and precision medicine. The session highlights emerging multidisciplinary approaches addressing treatment resistance, recurrence, and unmet clinical needs.

Explore advances in prostate and genitourinary cancers, including kidney, bladder, testicular, and related malignancies. Discussions include molecular biomarkers, advanced imaging, hormonal therapies, targeted treatments, immunotherapy, surgery, radiation, treatment resistance, and precision medicine. The session highlights emerging approaches for diagnosis, risk stratification, treatment selection, and disease monitoring.

Focus on leukemia, lymphoma, multiple myeloma, and other hematologic malignancies. Topics include molecular classification, targeted therapies, immunotherapy, stem cell transplantation, CAR-T cell therapy, antibody-based treatments, minimal residual disease monitoring, resistance mechanisms, and emerging cellular therapies. Discussions highlight innovative strategies improving diagnosis, treatment, disease control, and long-term outcomes.

Explore biological, clinical, and therapeutic advances in childhood cancers. Topics include pediatric tumor biology, molecular diagnostics, genetic predisposition, targeted therapies, immunotherapy, surgery, radiation, treatment-related toxicities, survivorship, and precision medicine. The session highlights innovative strategies addressing pediatric-specific challenges while improving survival, quality of life, and long-term health outcomes.

Examine strategies for reducing cancer incidence through prevention, lifestyle modification, screening, vaccination, environmental risk reduction, and population-based interventions. Topics include tobacco control, nutrition, physical activity, obesity, occupational exposures, health disparities, risk assessment, and public health programs designed to reduce cancer burden and promote healthier populations.

Explore comprehensive approaches to cancer survivorship and supportive care throughout the cancer journey. Topics include quality of life, rehabilitation, psychosocial support, symptom management, treatment-related late effects, palliative care, survivorship planning, patient-centered care, and emerging technologies shaping future oncology practice. The session emphasizes holistic, long-term approaches to cancer care.